GlassScriptPhysician profile
Vijaya C Ramesh
NPI 1538234984
$3,105.20
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $66.88 · 2021: $1,275 · 2022: $763 · 2023: $573 · 2024: $17.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $756.96 | 2021 | |
| Abbvie INC. | $374.42 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $239.41 | 2021-2024 | Rexulti, Nuedexta |
| Supernus Pharmaceuticals, INC. | $207.51 | 2021-2023 | Qelbree |
| Allergan, INC. | $160.20 | 2019-2020 | |
| Alkermes, INC. | $136.40 | 2021-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.87 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $128.70 | 2021-2022 | |
| Lundbeck LLC | $125.70 | 2019-2023 | Rexulti |
| Tris Pharma INC | $119.04 | 2019-2023 | Dyanavel Xr |
| Corium, LLC | $115.16 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $109.27 | 2021-2022 | |
| Neos Therapeutics, LP | $99.49 | 2019 | |
| Ironshore Pharmaceuticals INC. | $63.46 | 2020-2023 | Jornay Pm |
| Indivior INC. | $57.64 | 2021-2023 | Perseris |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $49.32 | 2023 | Auvelity |
| Shire North American Group INC | $43.37 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $38.29 | 2022 | |
| Almatica Pharma LLC | $34.69 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $30.44 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $28.43 | 2019 | |
| Adlon Therapeutics L.P. | $19.38 | 2021 | |
| Brainsway USA INC | $16.75 | 2022 | |
| Owp Pharmaceuticals, INC. | $14.15 | 2022 | |
| Neuronetics, INC. | $8.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijaya Ramesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.